Patents by Inventor Michael J. Hornsby

Michael J. Hornsby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER
    Publication number: 20230265206
    Abstract: The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.
    Type: Application
    Filed: March 10, 2023
    Publication date: August 24, 2023
    Applicant: The Regents of the University of California
    Inventors: James A. WELLS, Alexander J. MARTINKO, Juan E. DIAZ, Michael J. HORNSBY
  • Antibodies against CDCP1 for the treatment and detection of cancer
    Patent number: 11603412
    Abstract: The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: March 14, 2023
    Assignee: The Regents of the University of California
    Inventors: James A. Wells, Alexander J. Martinko, Juan E. Diaz, Michael J. Hornsby
  • ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER
    Publication number: 20210179729
    Abstract: The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 17, 2021
    Applicant: The Regents of the University of California
    Inventors: James A. WELLS, Alexander J. MARTINKO, Juan E. DIAZ, Michael J. HORNSBY
  • BETA-DEFENSIN 2 GENETIC VARIATION PREDICTS H. PYLORI SUSCEPTIBILITY
    Publication number: 20120214705
    Abstract: The present invention relates to correlating high gene copy number and/or the overexpression of ?-defensin 2 (“BD2”) with susceptibility to disease conditions resulting from, associated with or mediated by Helicobacter pylori infection, for example, susceptibility to peptic ulcer, non-ulcer dyspepsia, gastric cancer (e.g., gastric adenocarcinoma), and mucosa associated lymphoid tissue (MALT) lymphoma.
    Type: Application
    Filed: September 27, 2010
    Publication date: August 23, 2012
    Applicant: The Regents Of The University Of California Office of Technology,
    Inventors: Charles L. Bevins, Jay V. Solnick, Michael J. Hornsby, Robert J. Kays
  • Container cover
    Patent number: D1018294
    Type: Grant
    Filed: November 8, 2021
    Date of Patent: March 19, 2024
    Assignee: TARGET BRANDS, INC.
    Inventors: Richard P. Riedel, Terrence J. Hornsby, Jr., Michael M. Habig